综述:富马酸丙酚替诺福韦、富马酸替诺福韦二吡呋酯与恩替卡韦治疗慢性乙型肝炎的肾脏安全性
本文为叙述性综述,评估恩替卡韦(ETV)、富马酸替诺福韦二吡呋酯(TDF)和富马酸丙酚替诺福韦(TAF)在慢性乙型肝炎(CHB)一般及特殊人群中的肾脏安全性。基于随机与真实世界证据,TDF在基线中重度慢性肾病(CKD)患者中肾毒性可能高于ETV,但无或轻度肾损伤者两者安全性相似;TAF肾毒性显著低于TDF,且回顾性数据显示TAF可能比ETV更利于改善肾功能。
要点
- 无或轻度肾损伤的CHB患者中,ETV、TDF、TAF肾脏安全性相当,但证据渐倾向于TAF。
- 基线中重度CKD患者中,TDF肾毒性可能高于ETV。
- 随机数据显示TAF肾毒性显著低于TDF;回顾性数据提示TAF可能比ETV更利于改善肾功能。
核心结论
- 当前一线核苷(酸)类似物在无或轻度肾功能不全的CHB患者中肾脏安全性相当,但越来越多的证据支持TAF。
研究设计与样本
- 叙述性综述,通过PubMed多关键词检索相关研究,并手动筛查参考文献列表补充来源。
主要发现
- 基于随机和真实世界证据,基线中重度CKD患者中TDF肾毒性可能高于ETV,但无或轻度肾损伤者两者肾脏安全性相似。
- 随机数据显示TAF在不同临床场景中肾毒性显著低于TDF。
- 回顾性数据(初治和经治患者及特殊人群,包括肾损伤、肾移植、高龄和慢加急性肝衰竭)提示TAF可能比ETV更利于改善肾功能。
临床怎么用
- 无或轻度肾功能不全的CHB患者可考虑一线核苷(酸)类似物,证据渐倾向于TAF。
- 基线中重度CKD患者应避免TDF,优先考虑TAF或ETV。
- 特殊人群(肾损伤、肾移植、高龄、慢加急性肝衰竭)使用TAF可能更利于肾功能改善。
局限性
- 需前瞻性研究验证现有发现。
- 未来研究应关注有CKD风险的糖尿病CHB患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Renal safety is an important consideration for treatment selection in chronic hepatitis B (CHB) because of the ageing population and increasing prevalence of medical comorbidities. However, the renal safety profiles of first-line nucleos(t)ide analogues (NUCs) for CHB-tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), and entecavir (ETV) have not been comprehensively reviewed. AIMS: To evaluate the renal safety of ETV, TDF, and TAF in general and special populations with CHB. METHODS: In this narrative review, relevant studies in PubMed were identified using a range of keywords, followed by manual screening of reference lists to capture additional sources. RESULTS: Based on current randomised and real-world evidence, TDF may cause more nephrotoxic effects than ETV in patients with pre-existing moderate-to-severe chronic kidney disease (CKD), but the two agents may have similar renal safety profiles among patients with no or mild baseline renal impairment. Randomised data showed that TAF is significantly less nephrotoxic than TDF in different clinical settings. Retrospective data from both treatment-naïve and -experienced patients, as well as special populations, including patients with renal impairment, kidney transplant, advanced age, and acute-on-chronic liver failure, indicated that TAF may be more likely to improve renal function compared to ETV. CONCLUSIONS: Current first-line NUCs show comparable renal safety profiles in CHB patients with no or mild kidney dysfunction, with growing evidence that favours TAF. Future prospective studies are needed to validate these findings, and more research should focus on CHB patients with diabetes mellitus who are at risk of CKD.
引用
- Mak LY, Hu TH, Yap DYH, et al. Review Article: Renal Safety Profiles of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, and Entecavir for the Treatment of Chronic Hepatitis B Infection-General and Special Populations. Aliment Pharmacol Ther. 2026. PMID: 41630587. doi:10.1111/apt.70560
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。